Wedo Venture Partners

What Wedo Venture Partners does

Wedo Venture Partners is a privately held, cross-border venture capital firm founded in 2016 and headquartered in Singapore, with a second operating entity in Beijing (Suzhou Wedo Venture Capital Partnership). The firm invests in early-stage biotechnology and medical technology companies, with a stated thesis of bridging science, culture and capital between East and West. Its 10+ person team of specialists in science, medicine and business is deployed across Singapore, Beijing, Hong Kong, Shanghai, Shenzhen, and California, and the firm operates multi-billion-RMB dual-currency (RMB and USD) funds focused on deep technology and cross-border early-stage innovation. Portfolio companies span molecular diagnostics (BioPerfectus), nanopore sequencing (Geneus), preclinical antibody discovery (Biocytogen), gene and cell therapy (Reforgene, NGGT, Hemacell), AI-driven covalent chemistry (Bridgene), first-in-class small molecules (Drugfarm), and exosomal platforms (Huixin Lifetech), totaling 30 portfolio companies across Singapore, China and the US, with 4 funds fully deployed and Fund 1 fully exited.

Wedo's business model follows the standard venture capital economics of management fees on committed and deployed capital plus carried interest on realizations. Deal sourcing is conducted through direct networking, industry events, and professional referrals rather than mass marketing, and the firm acts as an active investor, with team members serving as Interim CEO and Interim COO of portfolio companies. Distribution is direct equity investment into early-stage rounds (Pre-Seed through Series B). Notable value-add milestones brokered by or attributable to the firm include a $770M Takeda partnership with portfolio company Bridgene in February 2025, a Merck KGaA antibody-conjugate agreement with Biocytogen in September 2025, and CE IVDR Mark plus commercial launch of the G-seq500 nanopore sequencer by Geneus in April 2026. Revenue is not publicly disclosed, consistent with private VC firm norms.

Name

Wedo Venture Partners

Legal name

Wedo Venture Partners Private Limited

Website

https://wedo.vc

Company type

Private

Founded year

2016

Operating status

Operating

Headcount range

11–50 employees

Short description

Wedo Venture Partners is a Singapore- and Beijing-based venture capital firm, founded in 2016, that invests in early-stage biotech and medtech companies across China, the US and Singapore, managing multi-billion-RMB dual-currency funds to bridge East-West science, clinical resources and capital.

Ownership category

akta.pro rank

Product category

Venture Capital (Biotech and Medtech Fund Management)

NAICS

Portfolio Management and Investment Advice (523940), Securities, Commodity Contracts, and Other Financial Investments and Related Activities (523)

SIC

Investment Advice (6282)

akta.pro primary industry

Sector-Focused Venture Capital (Vertical Specialists) (FSANAAAD)

Keywords

• Cross-border venture capital
• Biotech early-stage investing
• Medtech venture funding
• Healthcare fund management
• Deep technology investments

Headquarters

HQ city

Singapore

HQ country

Singapore

HQ region

Asia

Offices2 records

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Operations, Marketing or Sales, Technology or R&D, Others

Revenue model

1. Venture Capital Fund Management: Wedo Venture Partners generates revenue through management fees and carried interest from their portfolio funds. They have 4 portfolio funds fully deployed, with Fund 1 achieving a full exit with outstanding performance.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels2 records

Core offering

Wedo Venture Partners is a cross-border venture capital firm that invests equity capital from its four portfolio funds into early-stage biotech and medtech companies across Singapore, China, and the United States. Beyond capital, the firm provides strategic guidance, portfolio incubation, and access to Asia's clinical resources, talent, and supply networks, working with founders toward IPOs, acquisitions, and partnerships. Revenue is generated through fund management fees and carried interest on exits.

Product overview

Wedo Venture Partners is a venture capital firm, not a product or technology company. The firm provides investment funding and strategic support to early-stage biotech and medtech ventures. Its investment portfolio includes portfolio companies such as BioPerfectus (molecular diagnostics), Bridgene Biosciences (AI-powered covalent small molecule drug discovery), Huixin Lifetech (exosomal purification platform), NGGT (AAV-based gene therapy), Drugfarm (ALPK1 inhibitors), Biocytogen (preclinical research models and antibody discovery), Geneus (nanopore gene sequencing), Hemacell (stem cell therapy), and Reforgene (gene editing therapy). The firm does not offer proprietary products or services beyond investment and portfolio company support.

Differentiator

Problem solved

Functional benefit

Products and services

• Cross-Border Venture Capital Fund Investment

Quantifiable outcome

• Fund 1 has achieved a full exit with outstanding performance

Named customers9 records

Segments1 record

Ideal customer profiles1 record

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Partnerships

Two partnerships are on record, tiered portfolio.

• Merck KGaA, Darmstadt, GermanyportfolioStrategic or Co-development Partner · 3 September 2025Biocytogen, a Wedo portfolio company, entered into agreement with Merck KGaA to advance antibody-conjugated lipid-based delivery solutions.
• TakedaportfolioStrategic or Co-development Partner · 25 February 2025BridGene, a Wedo portfolio company, signed a $770M Takeda immunology, neurology deal.

Scale indicators4 records

Recent moves6 records

Expansion highlights6 records

Broad incumbents

• ARCH Venture Partners: US-based biotech-specialist VC focused on early-stage and clinical-stage life sciences. Comparable as a science-led, healthcare-dedicated VC with cross-border pharma exit outcomes.
• OrbiMed: Global healthcare-dedicated investment firm with venture, growth, and credit strategies across biotech, medtech, and diagnostics. Comparable as a sector-specialist healthcare investor with broader scale and a wider stage range than Wedo.
• Hillhouse Capital: Asia-rooted, multi-strategy investment firm with a substantial healthcare/biotech allocation. Comparable on cross-border Asia–US science investing mandate, though larger and more diversified than Wedo.
• Bain Capital Life Sciences: Healthcare-dedicated arm of Bain Capital spanning venture, growth, and public equities in biotech and medtech. Comparable as a thesis-driven, sector-specialist healthcare investor at much larger scale.

Direct peers

• Vivo Capital: Healthcare-specialist investment firm covering venture, growth, and public healthcare across US and Asia. Closely comparable on cross-border healthcare mandate and clinical-to-commercial stage focus.
• C-Bridge Capital: Asia-focused healthcare investment platform connecting China/Asia science to global pharma and capital markets. Highly comparable cross-border specialist with similar clinical-stage biotech profile.
• Northern Light Venture Capital: China-focused early-stage tech and healthcare VC where founder Summer Qu previously served as Executive Director. Closest stylistic precedent for Wedo's dual-currency, cross-border early-stage innovation mandate.
• Vickers Venture Partners: Singapore-based deep-tech and life sciences VC where partner Xinhong Lim previously ran the Silicon Valley office. Direct peer on cross-border, science-led investment mandate and Singapore HQ.
• Qiming Venture Partners: China-rooted, sector-specialist VC with deep healthcare/biotech franchise. Directly comparable to Wedo in thesis (China-based science, cross-border scaling), stage focus, and dual-currency structure, but at much larger scale.

Regional players

• Legend Capital: China-rooted VC with a dedicated healthcare franchise focused on early-to-growth biotech and medtech. Comparable on geographic focus and stage, though primarily China-domiciled rather than pan-Asia/US.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks5 records

Key highlights7 records

Customer concentration

Revenue estimate

Valuation estimate

Number of profiles

Profiles11 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments18 records

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Wedo Venture Partners